{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:50:41Z","timestamp":1791561041286,"version":"4.3.4"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T00:00:00Z","timestamp":1758672000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Burkitt lymphoma (BL) is a highly aggressive pediatric B-cell lymphoma with marked geographic heterogeneity. Up-to-date global estimates are needed to inform prevention and care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed Global Burden of Disease (GBD) 2021 data to estimate incidence, mortality, and disability-adjusted life years (DALYs) for childhood BL (0\u201314\u202fyears) from 1990 to 2021 across 204 countries\/territories, stratified by sex, age, region, and Sociodemographic Index (SDI). Trends were summarized using joinpoint annual percent change and estimated annual percentage change (EAPC). Bayesian age-period-cohort models projected the burden to 2035.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>In 2021, there were 4,083 incident BL cases globally [95% uncertainty interval (UI) 2,688\u20135,171]. The global incidence rate was 0.20 per 100,000 (95% UI 0.13\u20130.26) versus 0.16 per 100,000 (95% UI 0.10\u20130.23) in 1990. Burden varied substantially by development level: the low-SDI region had the highest incidence rate (0.44 per 100,000, 95% UI 0.26\u20130.59), mortality rate (0.43 per 100,000, 95% UI 0.25\u20130.58), and DALY rate (36.19 per 100,000, 95% UI 21.00\u201348.64). High-SDI regions showed lower mortality rates and evidence of declines, consistent with broader access to timely diagnosis, multi-agent chemotherapy, and supportive care. By 2035, the incidence rate is expected to reach 0.15 (95% CI 0.11\u20130.19) per 100,000, the mortality rate to 0.10 (95% CI 0.07\u20130.13) per 100,000, and the DALY rate to 8.21 (95% CI 5.98\u201310.43) per 100,000.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interpretation<\/jats:title>\n                    <jats:p>Global BL rates appear broadly stable, with pronounced inequities concentrated in low-SDI settings. Apparent improvements are heterogeneous, not universal, and are most evident in high-SDI regions where treatment and supportive care are widely available. Projections to 2035 suggest modest declines in global rates, contingent on sustained malaria control and expanded access to diagnosis and curative therapy in high-burden regions. Targeted investments linking infection control with pediatric oncology capacity are required to reduce the global burden of childhood BL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1619750","type":"journal-article","created":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:42:19Z","timestamp":1758692539000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Global burden of childhood Burkitt lymphoma (1990\u20132021): epidemiological trends, regional disparities, and projections for 2035 from the Global Burden of Disease Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Guoqian","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changyu","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,24]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1056\/NEJMra2025746","article-title":"Burkitt\u2019s lymphoma","volume":"387","author":"Roschewski","year":"2022","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1111\/bjh.13969","article-title":"Recent molecular and therapeutic advances in B-cell non-Hodgkin lymphoma in children","volume":"173","author":"Giulino-Roth","year":"2016","journal-title":"Br J Haematol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1002\/ijc.24223","article-title":"Epstein-Barr virus and the pathogenesis of Burkitt\u2019s lymphoma: more questions than answers","volume":"124","author":"Bornkamm","year":"2009","journal-title":"Int J Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nature11378","article-title":"Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics","volume":"490","author":"Schmitz","year":"2012","journal-title":"Nature"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ebiom.2018.12.041","article-title":"Epstein-Barr virus, malaria and endemic Burkitt lymphoma","volume":"39","author":"Velavan","year":"2019","journal-title":"EBioMedicine"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.semcancer.2009.10.002","article-title":"Endemic Burkitt\u2019s lymphoma as a polymicrobial disease: new insights on the interaction between plasmodium falciparum and Epstein-Barr virus","volume":"19","author":"Chene","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/apm.13018","article-title":"Endemic Burkitt lymphoma\u2014an aggressive childhood cancer linked to plasmodium falciparum exposure, but not to exposure to other malaria parasites","volume":"128","author":"Quintana","year":"2020","journal-title":"APMIS"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/00002030-199408000-00003","article-title":"Pathogenesis of AIDS lymphomas","volume":"8","author":"Herndier","year":"1994","journal-title":"AIDS"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"510","DOI":"10.4103\/0366-6999.151106","article-title":"Clinicopathological study of sporadic Burkitt lymphoma in children","volume":"128","author":"Huang","year":"2015","journal-title":"Chin Med J"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e202101355","DOI":"10.26508\/lsa.202101355","article-title":"Endemic Burkitt lymphoma avatar mouse models for exploring inter-patient tumor variation and testing targeted therapies","volume":"6","author":"Saikumar Lakshmi","year":"2023","journal-title":"Life Sci Alliance"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1016\/s2352-3026(20)30126-5","article-title":"HIV-associated Burkitt lymphoma","volume":"7","author":"Atallah-Yunes","year":"2020","journal-title":"Lancet Haematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1016\/s0140-6736(11)61177-x","article-title":"Burkitt\u2019s lymphoma","volume":"379","author":"Molyneux","year":"2012","journal-title":"Lancet"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.3324\/haematol.2013.086827","article-title":"High cure rates in Burkitt lymphoma and leukemia: a northern Italy leukemia group study of the German short intensive rituximab-chemotherapy program","volume":"98","author":"Intermesoli","year":"2013","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/s41408-024-01138-z","article-title":"Global, regional, and national burden of Burkitt lymphoma from 1990 to 2021 and predictions to 2030: a systematic analysis for the Global Burden of Disease Study 2021","volume":"14","author":"Wang","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1016\/s0140-6736(24)00757-8","article-title":"Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/s0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/s0140-6736(07)61602-x","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","year":"2020","journal-title":"Lancet"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12874-020-01133-5","article-title":"An R package for an integrated evaluation of statistical approaches to cancer incidence projection","volume":"20","author":"Knoll","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"994619","DOI":"10.3389\/fpubh.2022.994619","article-title":"Long-term trends in the burden of inflammatory bowel disease in China over three decades: a joinpoint regression and age-period-cohort analysis based on GBD 2019","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"102713","DOI":"10.1016\/j.eclinm.2024.102713","article-title":"Global, regional, and national burden of female cancers in women of child-bearing age, 1990\u20132021: analysis of data from the Global Burden of Disease Study 2021","volume":"74","author":"Sun","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1634\/theoncologist.11-4-375","article-title":"Burkitt\u2019s lymphoma: clinicopathologic features and differential diagnosis","volume":"11","author":"Ferry","year":"2006","journal-title":"Oncologist"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/nrmicro1089","article-title":"Endemic Burkitt\u2019s lymphoma: a polymicrobial disease?","volume":"3","author":"Rochford","year":"2005","journal-title":"Nat Rev Microbiol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"e62827","DOI":"10.7759\/cureus.62827","article-title":"Composite Burkitt lymphoma and classical Hodgkin lymphoma in an human immunodeficiency virus (HIV)-positive patient","volume":"16","author":"Smith","year":"2024","journal-title":"Cureus"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"111","DOI":"10.3390\/jcm6120111","article-title":"Viral oncology: molecular biology and pathogenesis","volume":"6","author":"Mui","year":"2017","journal-title":"J Clin Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41531-023-00535-8","article-title":"Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson\u2019s disease","volume":"9","author":"M\u00fcller-Nedebock","year":"2023","journal-title":"NPJ Parkinsons Dis"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41416-024-02937-8","article-title":"Patterns of incident Burkitt lymphoma during the HIV epidemic among the black African and white population in South Africa","volume":"132","author":"Metekoua","year":"2025","journal-title":"Br J Cancer"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coviro.2016.09.006","article-title":"Malaria\u2014how this parasitic infection aids and abets EBV-associated Burkitt lymphomagenesis","volume":"20","author":"Moormann","year":"2016","journal-title":"Curr Opin Virol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e70040","DOI":"10.1111\/sji.70040","article-title":"TCF3 and ID3 regulate TSPAN32 expression in Burkitt lymphoma","volume":"102","author":"Scuderi","year":"2025","journal-title":"Scand J Immunol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e01332-19","DOI":"10.1128\/mBio.01332-19","article-title":"Epstein-Barr virus infection promotes epithelial cell growth by attenuating differentiation-dependent exit from the cell cycle","volume":"10","author":"Eichelberg","year":"2019","journal-title":"mBio"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/dj13010006","article-title":"Sporadic Burkitt lymphoma first presenting as painful gingival swellings and tooth hypermobility: a life-saving referral","volume":"13","author":"Papadopoulou","year":"2024","journal-title":"Dent J"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/j.virs.2022.07.007","article-title":"Epidemiological characteristics and disease burden of infectious mononucleosis in hospitalized children in China: a nationwide retrospective study","volume":"37","author":"Liu","year":"2022","journal-title":"Virol Sin"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"2333794X231223266","DOI":"10.1177\/2333794x231223266","article-title":"Childhood Hodgkin lymphoma in sub-Saharan Africa: a systematic review on the effectiveness of the use of chemotherapy alone","volume":"11","author":"Kabahweza","year":"2024","journal-title":"Glob Pediatr Health"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s13027-021-00370-7","article-title":"Malaria and cancer: a critical review on the established associations and new perspectives","volume":"16","author":"Ellis","year":"2021","journal-title":"Infect Agent Cancer"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1615\/critreveukargeneexpr.v21.i1.50","article-title":"Autophagy in tumor suppression and cancer therapy","volume":"21","author":"Kung","year":"2011","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1103737","DOI":"10.3389\/fviro.2023.1103737","article-title":"Malignancy and viral infections in sub-Saharan Africa: a review","volume":"3","author":"Diakite","year":"2023","journal-title":"Front Virol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"e247351","DOI":"10.1001\/jamanetworkopen.2024.7351","article-title":"Mosquito bed net use and Burkitt lymphoma incidence in sub-Saharan Africa: a systematic review and Meta-analysis","volume":"7","author":"Schmit","year":"2024","journal-title":"JAMA Netw Open"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa1915315","article-title":"Rituximab for high-risk, mature B-cell non-Hodgkin\u2019s lymphoma in children","volume":"382","author":"Minard-Colin","year":"2020","journal-title":"N Engl J Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"e30565","DOI":"10.1002\/pbc.30565","article-title":"Children\u2019s Oncology Group\u2019s 2023 blueprint for research: non-Hodgkin lymphoma","author":"El-Mallawany","year":"2023","journal-title":"Pediatr Blood Cancer"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/1750-9378-8-36","article-title":"Factors influencing time to diagnosis and initiation of treatment of endemic Burkitt lymphoma among children in Uganda and western Kenya: a cross-sectional survey","volume":"8","author":"Buckle","year":"2013","journal-title":"Infect Agent Cancer"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e27621","DOI":"10.1002\/pbc.27621","article-title":"Outcome of pediatric non-Hodgkin lymphoma in Central America: a report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA)","volume":"66","author":"Pe\u00f1a-Hernandez","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1182\/bloodadvances.2020002178","article-title":"Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa","volume":"4","author":"El-Mallawany","year":"2020","journal-title":"Blood Adv"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1002\/pbc.21452","article-title":"Treatment of B-cell lymphoma with LMB modified protocols in Africa\u2014report of the French-African Pediatric Oncology Group (GFAOP)","volume":"50","author":"Harif","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pbc.22746","article-title":"Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP)","volume":"56","author":"Traor\u00e9","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1002\/ijc.33948","article-title":"Global patterns of Hodgkin lymphoma incidence and mortality in 2020 and a prediction of the future burden in 2040","volume":"150","author":"Singh","year":"2022","journal-title":"Int J Cancer"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1619750\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T05:42:21Z","timestamp":1758692541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1619750\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,24]]},"references-count":45,"alternative-id":["10.3389\/fmed.2025.1619750"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1619750","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,24]]},"article-number":"1619750"}}